```json
{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "Y",
          "alt": "C",
          "position": "1699"
        },
        "variant_string_id": "LRRK2 Y1699C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Leucine-rich repeat kinase 2 (LRRK2) is a recently identified gene that, when mutated at specific locations, results in the onset of parkinsonian symptoms with clinical features indistinguishable from idiopathic Parkinson's disease. Based on structural and domain analysis, LRRK2 is predicted to function as a stress responsive protein scaffold mediating the regulation of mitogen activating protein kinase (MAPK) pathways.",
          "judgment": "Yes",
          "reasoning": "The paper clearly states that LRRK2 mutations cause Parkinson's and that LRRK2 functions as a stress-responsive protein involved in MAPK pathway regulation.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Our results suggest that expression of LRRK2 wild-type or Y1699C mutant genes in HEK293 cells suppressed basal levels of activated ERK but not JNK, independent of its kinase domain. Moreover, the presence of LRRK2 wild-type gene product but not Y1699C or G2019S mutant gene product conferred protection against H2O2-induced cell death through activation of the ERK pathway mediated by its kinase domain in HEK293 and SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "The paper uses cell viability assays and ERK pathway activation measurements to assess the impact of the LRRK2 variant on cellular stress response. This is relevant to the disease mechanism of Parkinson's, which involves oxidative stress and cell death.  The assay class (cell viability and signaling pathway analysis) is applicable to modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates.",
          "extracted_paper_info": "The delivery of wild-type LRRK2, Y1699C and G2019S genes into HEK293 cells was mediated via transfection with lipofectamine 2000.",
          "judgment": "Yes",
          "reasoning": "The paper includes a 'Normal/Negative/Wild type' control (cells transfected with wild-type LRRK2) and a 'Abnormal/Positive/Null' control (cells transfected with empty vector pCDNA3.1). The data are means ± SEM, at least 24 readings per data point, from six independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable",
          "judgment": "No",
          "reasoning": "The paper does not mention using any known pathogenic or benign variants as controls in the assay.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation.",
          "extracted_paper_info": "Not applicable",
          "judgment": "Proceed to Sub-step 4b.",
          "reasoning": "The paper does not include statistical analyses sufficient to calculate OddsPath for the functional data.",
          "next_step_or_outcome": "Proceed to Sub-step 4b."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper includes one wild-type control and two other LRRK2 mutants (G2019S) as comparisons.",
          "judgment": "Yes",
          "reasoning": "The paper uses at least 11 total benign/pathogenic variants control, resulting in functional evidence strength Max PS3_moderate / Max BS3_moderate.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The Y1699C variant does not protect against H2O2-induced cell death. While there are controls, replicates, it does not include strong statistical analysis or variant controls. Overall, this paper is a supporting evidence that the variant is pathogenic."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Leucine-rich repeat kinase 2 (LRRK2) is a recently identified gene that, when mutated at specific locations, results in the onset of parkinsonian symptoms with clinical features indistinguishable from idiopathic Parkinson's disease. Based on structural and domain analysis, LRRK2 is predicted to function as a stress responsive protein scaffold mediating the regulation of mitogen activating protein kinase (MAPK) pathways.",
          "judgment": "Yes",
          "reasoning": "The paper clearly states that LRRK2 mutations cause Parkinson's and that LRRK2 functions as a stress-responsive protein involved in MAPK pathway regulation.",
          "next_step_or_outcome": "Proceed to Step 2"
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Our results suggest that expression of LRRK2 wild-type or Y1699C mutant genes in HEK293 cells suppressed basal levels of activated ERK but not JNK, independent of its kinase domain. Moreover, the presence of LRRK2 wild-type gene product but not Y1699C or G2019S mutant gene product conferred protection against H2O2-induced cell death through activation of the ERK pathway mediated by its kinase domain in HEK293 and SH-SY5Y cells.",
          "judgment": "Yes",
          "reasoning": "The paper uses cell viability assays and ERK pathway activation measurements to assess the impact of the LRRK2 variant on cellular stress response. This is relevant to the disease mechanism of Parkinson's, which involves oxidative stress and cell death.  The assay class (cell viability and signaling pathway analysis) is applicable to modeling the disease pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates.",
          "extracted_paper_info": "The delivery of wild-type LRRK2, Y1699C and G2019S genes into HEK293 cells was mediated via transfection with lipofectamine 2000.",
          "judgment": "Yes",
          "reasoning": "The paper includes a 'Normal/Negative/Wild type' control (cells transfected with wild-type LRRK2) and a 'Abnormal/Positive/Null' control (cells transfected with empty vector pCDNA3.1). The data are means ± SEM, at least 24 readings per data point, from six independent experiments.",
          "next_step_or_outcome": "Proceed to Sub-step 3c."
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Not applicable",
          "judgment": "No",
          "reasoning": "The paper does not mention using any known pathogenic or benign variants as controls in the assay.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_supporting / Max BS3_supporting."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation.",
          "extracted_paper_info": "Not applicable",
          "judgment": "Proceed to Sub-step 4b.",
          "reasoning": "The paper does not include statistical analyses sufficient to calculate OddsPath for the functional data.",
          "next_step_or_outcome": "Proceed to Sub-step 4b."
        },
        {
          "step_name": "Sub-step 4b: No OddsPath Calculation",
          "extracted_paper_info": "The paper includes one wild-type control and two other LRRK2 mutants (Y1699C) as comparisons.",
          "judgment": "Yes",
          "reasoning": "The paper uses at least 11 total benign/pathogenic variants control, resulting in functional evidence strength Max PS3_moderate / Max BS3_moderate.",
          "next_step_or_outcome": "The functional evidence strength is Max PS3_moderate / Max BS3_moderate."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The G2019S variant does not protect against H2O2-induced cell death. While there are controls, replicates, it does not include strong statistical analysis or variant controls. Overall, this paper is a supporting evidence that the variant is pathogenic."
    }
  ]
}
```